Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502339305

Ubpbio A covalent inhibitor of 3CL protease. A component of Paxlovid used for the treatment of COVID 19. CAS# 26288280-40-8, > 99% purity

Catalog No. 502339305
Encompass_Preferred

PF-07321332 is an orally active covalent inhibitor of the 3C-like protease by direct binding of the catalytic cysteine 145. 3CL protease cleaves polyproteins 1a and 1ab of SARS-CoV-2, a step required for reproduce the virus. The PF-07321332/ritonavir combination drug (trade name Paxlovid) is efficient for the treatment of COVID-19 as, in November 2021, Pfizer announced phase 2/3 clinal trial results that the drug treatment reduced 89% in hospitalizations when given within three days after symptom onset. This product is for research use only.

Catalog No. 50-233-9305 Supplier Ubpbio Supplier No. F100010
May include imposed supplier surcharges.
Add to Cart
Add to Cart

PF-07321332 is an orally active covalent inhibitor of the 3C-like protease by direct binding of the catalytic cysteine 145. 3CL protease cleaves polyproteins 1a and 1ab of SARS-CoV-2, a step required for reproduce the virus. The PF-07321332/ritonavir combination drug (trade name Paxlovid) is efficient for the treatment of COVID-19 as, in November 2021, Pfizer announced phase 2/3 clinal trial results that the drug treatment reduced 89% in hospitalizations when given within three days after symptom onset. This product is for research use only.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.